Our Motto - "Know. Now."
Brevitest Technologies, Inc. is a CLIA-certified clinical laboratory that leverages automation and cloud computing to deliver lab-quality results in 15 minutes, allowing our customers to “Know. Now.”
Our Story – Making Complex Lab Tests Simple
In 2013, we started as a humble sketch on a whiteboard, visualizing a way to make the complex
reactions in a typical enzyme-linked immunosorbent assay (ELISA) so fast, easy, and reliable
that almost anyone could run an immunoassay in less than 15 minutes
The inventors of the Brevitest platform – Dev Chatterjee, MD, PhD, Atul Varadhachary, MD, PhD, and Leo Linbeck III worked together at Fannin Innovation Studio, Houston’s most active early stage biotech and medtech development company. Believing that there had to be a faster, easier way to run immunoassays – one of the most important and ubiquitous types of lab tests – the three of them set out to find just such a way.
After proof of concept, we filed our first patent in 2014. That same year, Brevitest’s first working prototype (built by Dev out of Lego!) was shown at the annual Goradia Innovation Prize competition, where the concept garnered second prize. After several prototype revisions, we took home the Texas New Ventures Competition prize in 2015 and were awarded an SBIR grant by the National Institutes of Health to explore the potential of using the technology for drugs of abuse testing. This work was later expanded with the support of a larger, Phase II grant from NIH.
After developing these assays, however, the COVID-19 pandemic struck and we pivoted to COVID-19 diagnostics. In August 2021, Brevitest became the first company to successfully complete a clinical validation study for a quantitative IgG assay against SARS-CoV-2 from a single fingerstick. The quantitation was benchmarked to the international WHO standard for COVID-19 IgG. In September, we launched our assay for commercialization.
From 2013 to 2021, it has been a long journey to bring the concept to clinical adoption and commercialization. During this rewarding journey, our mission has not changed – to make diagnostic knowledge of one’s own biological status available to everyone in real time. In other words, to make sure that you “Know. Now.”
Leo Linbeck III
CEO and Chief Engineer
Chief Scientific Officer